Abstract
Six adults with refractory acute lymphocytic leukemia (ALL) were treated with high‐dose methotrexate, citrovorum factor, and vincristine. All patients had previously received extensive treatment with standard therapeutic agents, including vincristine, and all but one had received prior methotrexate. Two patients achieved complete remission and one achieved partial remission. Responses were seen at 3–6 gm/m2 of methotrexate. The durations of remission were 7–10 weeks. High‐dose methotrexate with citrovorum factor is effective in the treatment of advanced ALL and should be considered for inclusion in initial combination chemotherapeutic regimens for adult ALL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 79-84 |
| Number of pages | 6 |
| Journal | Medical and Pediatric Oncology |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1978 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- acute lymphocytic leukemia
- chemotherapy
- high‐dose methotrexate
Fingerprint
Dive into the research topics of 'High‐dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS